Sandy Feng1, Anthony J Demetris2, Katharine M Spain3, Sai Kanaparthi4, Bryna E Burrell4, Udeme D Ekong5, Estella M Alonso6, Philip Rosenthal1,7, Laurence A Turka4, David Ikle3, Nadia K Tchao4. 1. Department of Surgery, University of California San Francisco, San Francisco, CA. 2. Department of Pathology, University of Pittsburgh, Pittsburgh, PA. 3. Rho, Chapel Hill, NC. 4. Immune Tolerance Network, Bethesda, MD. 5. Department of Pediatrics, Yale School of Medicine, New Haven, CT. 6. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL. 7. Department of Pediatrics, University of California San Francisco, San Francisco, CA.
Abstract
Pediatric liver transplant recipients arguably have the most to gain and the most to lose from discontinuing immunosuppression (IS). Whereas IS undoubtedly exerts a cumulative toll, there is concern that insufficient or no IS may contribute to allograft deterioration. Twelve pediatric recipients of parental living donor liver grafts, identified as operationally tolerant through complete IS withdrawal (WISP-R; NCT00320606), were followed for a total of 5 years (1 year of IS withdrawal and 4 years off IS) with serial liver tests and autoantibody and alloantibody assessments. Liver biopsies were performed 2 and 4 years off IS, and, at these time points, immunoglobulin G (IgG) subclass and C1q binding activity for donor-specific antibodies (DSAs) were determined. There were no cases of chronic rejection, graft loss, or death. Allografts did not exhibit progressive increase in inflammation or fibrosis. Smooth-muscle actin expression by stellate cells and CD34 expression by liver sinusoidal endothelial cells remained stable, consistent with the absence of progressive graft injury. Three subjects never exhibited DSA. However, 3 subjects showed intermittent de novo class I DSA, 4 subjects showed persistent de novo class II DSA, and 5 subjects showed persistent preexisting class II DSA. Class II DSA was predominantly against donor DQ antigens, often of high mean fluorescence intensity, rarely of the IgG3 subclass, and often capable of binding C1q. CONCLUSION:Operationally tolerant pediatric liver transplant recipients maintain generally stable allograft histology in spite of apparently active humoral allo-immune responses. The absence of increased inflammation or progressive fibrosis suggests that a subset of liver allografts seem resistant to the chronic injury that is characteristic of antibody-mediated damage. (Hepatology 2017;65:647-660).
RCT Entities:
Pediatric liver transplant recipients arguably have the most to gain and the most to lose from discontinuing immunosuppression (IS). Whereas IS undoubtedly exerts a cumulative toll, there is concern that insufficient or no IS may contribute to allograft deterioration. Twelve pediatric recipients of parental living donor liver grafts, identified as operationally tolerant through complete IS withdrawal (WISP-R; NCT00320606), were followed for a total of 5 years (1 year of IS withdrawal and 4 years off IS) with serial liver tests and autoantibody and alloantibody assessments. Liver biopsies were performed 2 and 4 years off IS, and, at these time points, immunoglobulin G (IgG) subclass and C1q binding activity for donor-specific antibodies (DSAs) were determined. There were no cases of chronic rejection, graft loss, or death. Allografts did not exhibit progressive increase in inflammation or fibrosis. Smooth-muscle actin expression by stellate cells and CD34 expression by liver sinusoidal endothelial cells remained stable, consistent with the absence of progressive graft injury. Three subjects never exhibited DSA. However, 3 subjects showed intermittent de novo class I DSA, 4 subjects showed persistent de novo class II DSA, and 5 subjects showed persistent preexisting class II DSA. Class II DSA was predominantly against donor DQ antigens, often of high mean fluorescence intensity, rarely of the IgG3 subclass, and often capable of binding C1q. CONCLUSION: Operationally tolerant pediatric liver transplant recipients maintain generally stable allograft histology in spite of apparently active humoral allo-immune responses. The absence of increased inflammation or progressive fibrosis suggests that a subset of liver allografts seem resistant to the chronic injury that is characteristic of antibody-mediated damage. (Hepatology 2017;65:647-660).
Authors: Josh Levitsky; Bryna E Burrell; Sai Kanaparthi; Laurence A Turka; Sunil Kurian; Alberto Sanchez-Fueyo; Juan J Lozano; Anthony Demetris; Andrew Lesniak; Allan D Kirk; Linda Stempora; Guang-Yu Yang; James M Mathew Journal: Hepatology Date: 2020-06-08 Impact factor: 17.425
Authors: Sandy Feng; John C Bucuvalas; Anthony J Demetris; Bryna E Burrell; Katherine M Spain; Sai Kanaparthi; John C Magee; David Ikle; Andrew Lesniak; Juan J Lozano; Estella M Alonso; Robert A Bray; Nancy E Bridges; Edward Doo; Howard M Gebel; Nitika A Gupta; Ryan W Himes; Annette M Jackson; Steven J Lobritto; George V Mazariegos; Vicky L Ng; Elizabeth B Rand; Averell H Sherker; Shikha Sundaram; Yumirle P Turmelle; Alberto Sanchez-Fueyo Journal: Gastroenterology Date: 2018-08-23 Impact factor: 22.682
Authors: Alexander Kroemer; Khalid Khan; Stuart S Kaufman; Jiman Kang; Joshua Weiner; Anju Duttargi; Leonid Belyayev; Chethan Ashokkumar; Rakesh Sindhi; Olga A Timofeeva; Michael Zasloff; Cal S Matsumoto; Thomas M Fishbein Journal: Am J Transplant Date: 2020-08-30 Impact factor: 8.086
Authors: Jaap Kwekkeboom; Nicolle H R Litjens; Aafke A Duizendstra; Robert J de Knegt; Shanta Mancham; Mariska Klepper; Dave L Roelen; Simone H Brand-Schaaf; Patrick P Boor; Michail Doukas; Robert A de Man; Dave Sprengers; Maikel P Peppelenbosch; Michiel G H Betjes Journal: Liver Transpl Date: 2021-07-21 Impact factor: 6.112